rg 12525 has been researched along with midazolam in 1 studies
| Studies (rg 12525) | Trials (rg 12525) | Recent Studies (post-2010) (rg 12525) | Studies (midazolam) | Trials (midazolam) | Recent Studies (post-2010) (midazolam) |
|---|---|---|---|---|---|
| 14 | 3 | 0 | 9,834 | 3,191 | 3,301 |
| Protein | Taxonomy | rg 12525 (IC50) | midazolam (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 2.7427 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fayer, JL; Kirkesseli, S; Luo, Y; Sidhu, R; Stevens, JC; Zannikos, PN | 1 |
1 trial(s) available for rg 12525 and midazolam
| Article | Year |
|---|---|
Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Glucuronides; Half-Life; Humans; In Vitro Techniques; Leukotriene Antagonists; Male; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Models, Biological; Protein Binding; Quinolines; Receptors, Cytoplasmic and Nuclear; Tetrazoles; Transcription Factors | 2001 |